drugset / Trial / NCT00257283

Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis

NCT00257283

RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this investigator initated study is to examine the effect of OMACOR (Omega-3-acid ethyl ester 90) on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis, who has previously experienced a cardiovascular event.

Timeline

Start
2002-11
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lovaza Other / unclassified